Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.5
(0.93%)
USD 0.5
(0.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -32.49 Million USD | -335.58% |
| 2022 | -7.45 Million USD | 85.91% |
| 2021 | -52.94 Million USD | -80.79% |
| 2020 | -29.28 Million USD | -576.44% |
| 2019 | -4.32 Million USD | 79.7% |
| 2018 | -21.32 Million USD | 39.61% |
| 2017 | -35.3 Million USD | -94.99% |
| 2016 | -18.1 Million USD | 51.23% |
| 2015 | -37.12 Million USD | -28.2% |
| 2014 | -28.95 Million USD | -426.98% |
| 2013 | -5.49 Million USD | -26.33% |
| 2012 | -4.34 Million USD | 80.42% |
| 2011 | -22.21 Million USD | 33.35% |
| 2010 | -33.32 Million USD | -173.4% |
| 2009 | -12.18 Million USD | -750.63% |
| 2008 | 1.87 Million USD | 164.97% |
| 2007 | 707.03 Thousand USD | 226.03% |
| 2006 | -561.01 Thousand USD | 69.41% |
| 2005 | -1.83 Million USD | -33.78% |
| 2004 | -1.37 Million USD | -169.65% |
| 2003 | 1.96 Million USD | 122.55% |
| 2002 | 884.37 Thousand USD | 1028.4% |
| 2001 | 78.37 Thousand USD | 105.94% |
| 2000 | -1.31 Million USD | 75.09% |
| 1999 | -5.29 Million USD | -120.53% |
| 1998 | -2.4 Million USD | 69.23% |
| 1997 | -7.8 Million USD | -225.0% |
| 1996 | -2.4 Million USD | 29.41% |
| 1995 | -3.4 Million USD | -385.71% |
| 1994 | -700 Thousand USD | 53.33% |
| 1993 | -1.5 Million USD | 68.75% |
| 1992 | -4.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -40.32 Million USD | -24.11% |
| 2024 Q2 | -26.67 Million USD | 33.85% |
| 2023 Q2 | -30.48 Million USD | -158.04% |
| 2023 Q3 | -28.39 Million USD | 6.85% |
| 2023 FY | -32.49 Million USD | -335.58% |
| 2023 Q4 | -32.49 Million USD | -14.43% |
| 2023 Q1 | -11.81 Million USD | -58.37% |
| 2022 Q3 | -21.95 Million USD | 68.07% |
| 2022 FY | -7.45 Million USD | 85.91% |
| 2022 Q2 | -68.75 Million USD | 8.94% |
| 2022 Q1 | -75.5 Million USD | -42.62% |
| 2022 Q4 | -7.45 Million USD | 66.02% |
| 2021 FY | -52.94 Million USD | -80.79% |
| 2021 Q1 | -52.65 Million USD | -83.09% |
| 2021 Q4 | -52.94 Million USD | 8.87% |
| 2021 Q3 | -58.09 Million USD | 1.71% |
| 2021 Q2 | -59.1 Million USD | -12.23% |
| 2020 FY | -29.28 Million USD | -576.44% |
| 2020 Q3 | -29.72 Million USD | -292.46% |
| 2020 Q2 | -7.57 Million USD | -51.51% |
| 2020 Q1 | -4.99 Million USD | -15.48% |
| 2020 Q4 | -28.76 Million USD | 3.25% |
| 2019 Q3 | -9.05 Million USD | -171.4% |
| 2019 Q4 | -4.32 Million USD | 52.19% |
| 2019 Q2 | -3.33 Million USD | 74.18% |
| 2019 FY | -4.32 Million USD | 79.7% |
| 2019 Q1 | -12.92 Million USD | 39.41% |
| 2018 Q2 | -25.83 Million USD | 9.03% |
| 2018 Q4 | -21.32 Million USD | -19.55% |
| 2018 Q3 | -17.83 Million USD | 30.96% |
| 2018 Q1 | -28.39 Million USD | 19.57% |
| 2018 FY | -21.32 Million USD | 39.61% |
| 2017 Q1 | -20.1 Million USD | -11.05% |
| 2017 Q2 | -10.47 Million USD | 47.9% |
| 2017 Q3 | -15.22 Million USD | -45.32% |
| 2017 Q4 | -35.3 Million USD | -131.93% |
| 2017 FY | -35.3 Million USD | -94.99% |
| 2016 Q2 | -25.05 Million USD | -19.52% |
| 2016 FY | -18.1 Million USD | 51.23% |
| 2016 Q1 | -20.96 Million USD | 43.54% |
| 2016 Q3 | -27.26 Million USD | -8.82% |
| 2016 Q4 | -18.1 Million USD | 33.59% |
| 2015 Q4 | -37.12 Million USD | -50.77% |
| 2015 FY | -37.12 Million USD | -28.2% |
| 2015 Q1 | -25.02 Million USD | 13.59% |
| 2015 Q2 | -27.83 Million USD | -11.23% |
| 2015 Q3 | -24.62 Million USD | 11.53% |
| 2014 Q3 | -7.31 Million USD | 53.16% |
| 2014 FY | -28.95 Million USD | -426.98% |
| 2014 Q2 | -15.6 Million USD | -135.11% |
| 2014 Q1 | -6.63 Million USD | -20.79% |
| 2014 Q4 | -28.95 Million USD | -296.13% |
| 2013 Q4 | -5.49 Million USD | 18.19% |
| 2013 Q1 | -9.89 Million USD | -127.5% |
| 2013 Q2 | -14.3 Million USD | -44.56% |
| 2013 FY | -5.49 Million USD | -26.33% |
| 2013 Q3 | -6.71 Million USD | 53.05% |
| 2012 Q2 | -12.65 Million USD | 23.22% |
| 2012 Q4 | -4.34 Million USD | 44.45% |
| 2012 Q1 | -16.48 Million USD | 25.77% |
| 2012 FY | -4.34 Million USD | 80.42% |
| 2012 Q3 | -7.83 Million USD | 38.15% |
| 2011 FY | -22.21 Million USD | 33.35% |
| 2011 Q3 | -26.23 Million USD | 4.21% |
| 2011 Q4 | -22.21 Million USD | 15.32% |
| 2011 Q1 | -30.13 Million USD | 9.57% |
| 2011 Q2 | -27.38 Million USD | 9.14% |
| 2010 Q1 | -11.17 Million USD | 8.34% |
| 2010 FY | -33.32 Million USD | -173.4% |
| 2010 Q4 | -33.32 Million USD | -31.09% |
| 2010 Q3 | -25.42 Million USD | -40.79% |
| 2010 Q2 | -18.05 Million USD | -61.6% |
| 2009 Q4 | -12.18 Million USD | -56.13% |
| 2009 FY | -12.18 Million USD | -750.63% |
| 2009 Q1 | 2.97 Million USD | 58.98% |
| 2009 Q2 | -1.37 Million USD | -146.29% |
| 2009 Q3 | -7.8 Million USD | -466.27% |
| 2008 Q2 | 1.75 Million USD | 75.19% |
| 2008 FY | 1.87 Million USD | 164.97% |
| 2008 Q1 | 999.85 Thousand USD | 41.42% |
| 2008 Q4 | 1.87 Million USD | -30.39% |
| 2008 Q3 | 2.69 Million USD | 53.64% |
| 2007 Q1 | -177.28 Thousand USD | 68.4% |
| 2007 FY | 707.03 Thousand USD | 226.03% |
| 2007 Q4 | 707.03 Thousand USD | 107.85% |
| 2007 Q3 | 340.17 Thousand USD | 89.9% |
| 2007 Q2 | 179.12 Thousand USD | 201.04% |
| 2006 Q1 | -1.08 Million USD | 40.61% |
| 2006 FY | -561.01 Thousand USD | 69.41% |
| 2006 Q4 | -561.01 Thousand USD | 25.75% |
| 2006 Q3 | -755.55 Thousand USD | 24.4% |
| 2006 Q2 | -999.43 Thousand USD | 8.24% |
| 2005 Q2 | -588.54 Thousand USD | 17.31% |
| 2005 FY | -1.83 Million USD | -33.78% |
| 2005 Q1 | -711.76 Thousand USD | 48.08% |
| 2005 Q4 | -1.83 Million USD | -944.5% |
| 2005 Q3 | -175.56 Thousand USD | 70.17% |
| 2004 FY | -1.37 Million USD | -169.65% |
| 2004 Q4 | -1.37 Million USD | 12.63% |
| 2004 Q3 | -1.56 Million USD | 10.41% |
| 2004 Q2 | -1.75 Million USD | 17.39% |
| 2004 Q1 | -2.11 Million USD | -207.7% |
| 2003 FY | 1.96 Million USD | 122.55% |
| 2003 Q2 | 1.59 Million USD | 0.9% |
| 2003 Q4 | 1.96 Million USD | 54.66% |
| 2003 Q1 | 1.58 Million USD | 79.25% |
| 2003 Q3 | 1.27 Million USD | -20.43% |
| 2002 FY | 884.37 Thousand USD | 1028.4% |
| 2002 Q2 | 1.42 Million USD | 70.43% |
| 2002 Q1 | 837.13 Thousand USD | 968.12% |
| 2002 Q3 | 213.18 Thousand USD | -85.06% |
| 2002 Q4 | 884.37 Thousand USD | 314.85% |
| 2001 Q3 | 1.41 Million USD | 360.19% |
| 2001 Q1 | -321.51 Thousand USD | 75.61% |
| 2001 FY | 78.37 Thousand USD | 105.94% |
| 2001 Q4 | 78.37 Thousand USD | -94.45% |
| 2001 Q2 | 307.02 Thousand USD | 195.49% |
| 2000 Q3 | -2.02 Million USD | 16.74% |
| 2000 Q2 | -2.42 Million USD | 34.18% |
| 2000 Q1 | -3.68 Million USD | 30.33% |
| 2000 FY | -1.31 Million USD | 75.09% |
| 2000 Q4 | -1.31 Million USD | 34.76% |
| 1999 Q2 | -7.2 Million USD | 16.28% |
| 1999 Q3 | -6.6 Million USD | 8.33% |
| 1999 Q1 | -8.6 Million USD | 0.0% |
| 1999 Q4 | -5.29 Million USD | 19.81% |
| 1999 FY | -5.29 Million USD | -120.53% |
| 1998 Q2 | -4.1 Million USD | 19.61% |
| 1998 Q3 | -3.3 Million USD | 19.51% |
| 1998 Q1 | -5.1 Million USD | 19.05% |
| 1998 FY | -2.4 Million USD | 69.23% |
| 1997 Q3 | -7.4 Million USD | 5.13% |
| 1997 Q4 | -6.3 Million USD | 14.86% |
| 1997 FY | -7.8 Million USD | -225.0% |
| 1997 Q1 | -7.3 Million USD | -305.56% |
| 1997 Q2 | -7.8 Million USD | -6.85% |
| 1996 Q3 | -2 Million USD | 16.67% |
| 1996 FY | -2.4 Million USD | 29.41% |
| 1996 Q4 | -1.8 Million USD | 10.0% |
| 1996 Q2 | -2.4 Million USD | 0.0% |
| 1995 Q1 | -900 Thousand USD | 40.0% |
| 1995 Q2 | -3.4 Million USD | -277.78% |
| 1995 Q3 | -2.9 Million USD | 14.71% |
| 1995 FY | -3.4 Million USD | -385.71% |
| 1994 FY | -700 Thousand USD | 53.33% |
| 1994 Q3 | -200 Thousand USD | 71.43% |
| 1994 Q2 | -700 Thousand USD | 46.15% |
| 1994 Q1 | -1.3 Million USD | 51.85% |
| 1994 Q4 | -1.5 Million USD | -650.0% |
| 1993 FY | -1.5 Million USD | 68.75% |
| 1993 Q4 | -2.7 Million USD | -145.45% |
| 1993 Q3 | -1.1 Million USD | 26.67% |
| 1993 Q2 | -1.5 Million USD | 60.53% |
| 1993 Q1 | -3.8 Million USD | 7.32% |
| 1992 Q4 | -4.1 Million USD | 6.82% |
| 1992 Q3 | -4.4 Million USD | 8.33% |
| 1992 Q2 | -4.8 Million USD | 5.88% |
| 1992 Q1 | -5.1 Million USD | 0.0% |
| 1992 FY | -4.8 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | -557.16% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -751.638% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 130.408% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 56.427% |
| Azitra, Inc. | -910.04 Thousand USD | -3470.165% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | -666.635% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 2871.489% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 726.374% |
| CEL-SCI Corporation | 9.42 Million USD | 444.684% |
| iBio, Inc. | -9.75 Million USD | -233.231% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | -354.361% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -2436.3% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 7510.296% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -8230.769% |
| NanoViricides, Inc. | -4.79 Million USD | -577.188% |
| Oragenics, Inc. | -3.17 Million USD | -924.663% |
| BiomX Inc. | -772 Thousand USD | -4108.549% |
| BiomX Inc. | -772 Thousand USD | -4108.549% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 1327.427% |
| Palatin Technologies, Inc. | -8.93 Million USD | -263.542% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 334.464% |